Drugs / CRPA1A2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07583316 | May 2026 → Mar 2030 expected | esophageal cancer, head and neck cancer, hepatocellular carcinoma, lung cancer | Corregene Biotechnology Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRPA1A2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07583316 ↗ |
| Modality | Other / unclassified | “bispecific T-cell engager” NCT07583316 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT07583316 ↗ |